BIOS · Bioplus Acquisition Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | ($1.28M) | ($275.3K) | - | ($290.4K) | ($1.1K) | ($307.2K) | - | - |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | $1.24M | $2.32M | - | ($877) | ($1.1K) | ($261.8K) | - | - |
| EPS - Basic | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5K | $35.4K | $140.3K | $107.1K | $23.7K | $635.5K | $635.5K | $0 |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - |
| Current Assets | $196.8K | $447.1K | $548.8K | $628.6K | $715.5K | $817.1K | $1.00M | - |
| Total Assets | $138.63M | $240.82M | $238.32M | $236.51M | $235.81M | $235.78M | $235.98M | - |
| Current Liabilities | $1.98M | $700.5K | $526.9K | $288.5K | $241.5K | $239.7K | $179.1K | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.78M | $15.50M | $15.33M | $15.09M | $15.04M | $15.04M | $14.98M | - |
| Stockholders' Equity | ($16.58M) | ($15.05M) | ($14.78M) | ($14.46M) | $18.9K | ($13.86M) | ($13.60M) | $0 |
| Retained Earnings | ($16.58M) | ($15.05M) | ($14.78M) | ($14.46M) | ($14.17M) | ($13.86M) | $13.60M | - |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($315.6K) | - | - | - | ($166.5K) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | $210.7K | - | - | - | ($26.3K) | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | 0.9% | 1.0% | - | -0.0% | -0.0% | -0.1% | - | - |
| Return on equity | -7.5% | -15.4% | - | 0.0% | -6.0% | 1.9% | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.10 | 0.64 | 1.04 | 2.18 | 2.96 | 3.41 | 5.60 | - |
| Quick ratio | 0.10 | 0.64 | 1.04 | 2.18 | 2.96 | 3.41 | 5.60 | - |
| Cash ratio | 0.00 | 0.05 | 0.27 | 0.37 | 0.10 | 2.65 | 3.55 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | -8.36 | -16.00 | -16.13 | -16.36 | 12502.99 | -17.01 | -17.35 | - |
| Liabilities / Assets | 0.12 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -112092.2% | 10.4% | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -8.6% | -8.7% | - | - | - | - | - |
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing BioPlus Acquisition Corp. against the 5 most active filers in the same SIC group.